Blopress led sluggish Japanese market in 2008
This article was originally published in Scrip
Takeda's Blopress (candesartan) was again the top-selling prescription drug in Japan last year, although growth for both it and the wider market was constrained by the regular reimbursement price cut in April. This averaged 5.2% and meant that the total market expanded by just 3% to ¥8,254.3 billion ($83.8 billion), compared with growth of around 5% in 2007, an "off year" for the biennial price revision.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.